Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.

Area of Science:

• Oncolytic virotherapy
• Cancer immunotherapy
• Tumor microenvironment modulation

Background:

• Cancer immunotherapy faces challenges with 'cold' tumors, characterized by immune evasion and poor T-cell infiltration.
• Solid tumors present physical barriers and resistance to current immunotherapeutics, necessitating novel strategies.
• Existing immunotherapies have limitations, especially for diverse solid tumor types.

Purpose of the Study:

• To explore oncolytic viruses (OVs) as a synergistic platform for novel antitumor strategies.
• To investigate OV potential in overcoming tumor microenvironment (TME) limitations and enhancing immunotherapy efficacy.
• To highlight OVs' role in converting non-immunogenic tumors into immunogenic ones.

Main Methods:

• Review of recent advances in oncolytic virus engineering and tumor biology.
• Analysis of OV mechanisms including direct oncolysis, immunogenic cell death, and immune stimulation.
• Exploration of combinatorial strategies involving OVs and other therapeutics.

Main Results:

• Oncolytic viruses (OVs) induce direct tumor cell lysis and immunogenic cell death.
• OVs can reprogram the tumor microenvironment (TME) from 'cold' to 'hot', promoting T-cell infiltration.
• Engineered OVs demonstrate improved tumor selectivity, potency, and immune stimulation.

Conclusions:

• Oncolytic viruses (OVs) offer a multimodal approach to enhance cancer immunotherapy.
• OV-mediated tumor antigen release and immune stimulation can elicit potent antitumor immunity.
• Combinatorial strategies involving OVs hold significant potential for improving cancer treatment outcomes.